TriVascular Technologies (TRIV) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TriVascular Technologies, Inc. Reports Second Quarter Financial Results
August 4, 2015 4:02 PM EDTSANTA ROSA, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (NASDAQ: TRIV), manufacturer of the Ovation Prime® Abdominal Stent Graft System, today reported financial results for the second quarter ended June 30, 2015.
Recent Accomplishments:
Second quarter revenue of $9.7 million, up 24.8% over the second quarter of 2014 as reported, and 29.7% on a constant currency basis   Second quarter gross margin of 61.4%, an increase from 55.6% in the second quarter of 2014   Enrollment completed in FDA PMA post approval study; LIFE study enrollment exceeds 100 patients   FDA approval received for Ovation iX Abdominal Stent... More